Ingrid HobΓ¦k Haff (h-index 17; ~1,922 citations across 32+ papers) built her reputation on vine copula methodology. Her most influential theoretical work critically examined whether the simplified pair-copula construction β a core assumption enabling tractable vine inference β is "simply useful or too simplistic", a question that remains central to the field . Her single-author Bernoulli paper developed the stepwise semiparametric estimator with proven asymptotic properties β rigorous, theory-first statistics .
Her most-cited work (375 citations) applied pair-copula constructions to compound flood events in Ravenna, demonstrating how copula dependence modeling outperforms univariate analysis for multivariate climate extremes .
Since ~2020 she pivoted substantially into adaptive immune receptor repertoire (AIRR) machine learning at University of Oslo, contributing to the immuneML ecosystem and to the discovery that compact paratope-epitope interaction vocabularies make antibody-antigen binding predictable .
Strengths: methodological depth with proven asymptotics, cross-domain transfer (finance β hydrology β immunology), and co-authorship on high-impact platforms (Cell Reports, Nature Machine Intelligence, Nature Computational Science). Caveats: her strongest immunology outputs are as a middle/late author in large Oslo groups β the leadership and immunological domain knowledge likely sit with Akbar, Robert, and Sandve's group. The citation peak (2021β2024) is recent and partly driven by the antibody-design boom, so long-term citation durability is unproven. Citations in hydrology/finance stem from collaborative applied work rather than her core methodological identity. OpenAlex reports 54 works vs 32 indexed papers, indicating some methodological-count uncertainty.
Verdict: a rigorous mathematical statistician who successfully redeployed vine copula expertise into computational immunology β a genuine and increasingly valuable interdisciplinary asset, though her scientific identity is defined more by copula methodology than by immunology itself.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.